END-STAGE KIDNEY DISEASE

This study tests if a new drug called siplizumab can safely prevent kidney transplant rejection better than the current standard treatment. About 120 adults receiving a kidney transplant will be split into three groups: two groups get different doses of siplizumab, and one gets t…

This phase 3 trial tests whether ravulizumab, given intravenously, can reduce the severity of delayed graft function (DGF) in adults at high risk after kidney transplant. DGF is when the new kidney is slow to start working, often requiring dialysis. The study will compare ravuliz…

This study tests a new drug called AZD7760 in healthy volunteers and people with end-stage kidney disease who are on dialysis. The goal is to see if the drug is safe and how the body processes it. If it works, it could help prevent serious staph infections that often occur in dia…

This study tests a drug called CSL300 in people with end-stage kidney disease who are on dialysis and have signs of inflammation. The goal is to see if it can reduce the risk of heart attacks or heart-related death. About 3110 adults will take part, and half will get the drug whi…

This study tests whether a personalized, gradual start to dialysis is safer and improves quality of life compared to the standard fixed schedule. It involves 350 adults with end-stage kidney disease who recently started dialysis. Researchers will track hospital visits, overall he…

This study compares starting dialysis twice a week versus the standard three times a week in elderly patients (60+) with end-stage kidney disease who still produce some urine. The goal is to see if fewer sessions reduce hospitalizations, falls, and other complications while maint…

This study tests a special monitor that predicts low blood pressure during dialysis in ICU patients. The goal is to prevent dangerous drops by alerting doctors early. About 46 adults with kidney injury or failure will take part. If successful, this approach could make dialysis sa…

This study looks at different ways to give iron to people with kidney failure who are on peritoneal dialysis. Participants will get either high-dose or low-dose intravenous iron, or oral iron tablets. The main goal is to see if a larger trial is possible by checking how many peop…

This study tests whether a daily 25 mg dose of empagliflozin (a diabetes drug) is safe and helps preserve remaining kidney function in 20 adults on peritoneal dialysis. Participants must still produce at least 250 mL of urine daily. The trial measures changes in kidney filtration…

This early-phase trial tests a single dose of AZD0120, a CAR-T cell therapy that targets two immune proteins (CD19 and BCMA), in 12 highly sensitized adults with end-stage kidney disease awaiting a transplant. The goal is to safely reduce the antibodies that make finding a compat…

This Phase 3 trial tests an oral drug called AND017 for anemia in people on dialysis due to end-stage kidney disease. About 300 participants will receive either AND017 capsules or a standard injected ESA. The goal is to see if AND017 can maintain healthy hemoglobin levels as well…

This study looks at whether an automated insulin delivery system (the Medtronic 780G) can help adults with diabetes and advanced kidney disease manage their blood sugar better than their usual insulin injections. Participants will use the system for 8 weeks and then switch to the…

This phase 3 trial compares two common beta blockers—metoprolol and carvedilol—in about 2,540 hemodialysis patients. The goal is to see if metoprolol, which is removed by dialysis, leads to fewer major heart events like heart attacks, strokes, or heart failure hospitalizations. P…

This early-stage study tests whether a stem cell infusion from the same donor can allow kidney transplant recipients to safely stop taking lifelong anti-rejection medications. Ten adults with a well-functioning kidney from a matched living donor will receive a conditioning treatm…

This study is testing a new dialysis machine called Moda-flx for people with end-stage kidney disease who are already on stable dialysis. The goal is to see if the machine is safe and works well both in a clinic and at home when used by trained patients or care partners. About 50…

This study tests whether giving the antiviral drug remdesivir for 10 days can prevent severe COVID-19 in kidney transplant recipients who have mild or no symptoms. About 15 adults will receive the drug starting just before their transplant. The goal is to see if this approach all…

This study tests whether the drug patiromer can safely allow people on chronic dialysis to relax their strict low-potassium diet. About 40 participants will receive either patiromer or a placebo daily. The goal is to see if patiromer keeps potassium levels stable while patients e…

This study tests whether using social virtual reality (VR) during dialysis sessions can reduce loneliness and other symptoms in people with end-stage kidney disease. Sixty participants will use VR glasses for 30-45 minutes, three times a week, for four weeks. Researchers will com…

This study looks at a new way to do dialysis using just one needle in the arm instead of two, which may cause less damage to the blood vessel used for treatment. About 100 adults on long-term dialysis will try this method, and researchers will check if it keeps dialysis working w…

This study tests whether a symptom-monitoring system called SMaRRT-HD helps dialysis patients feel better. About 2,400 adults on hemodialysis at up to 36 U.S. clinics will either use the system or receive usual care. The system lets patients report symptoms on a tablet and alerts…

This study tests whether a 12-week aerobic exercise program (cycling) during hemodialysis sessions can improve sleep quality, depression, and anxiety in kidney patients. 100 adults on maintenance dialysis will be split into an exercise group and a control group. The goal is to se…

This study looks at how well the immune system works in people with end-stage kidney disease. Researchers will take blood samples from 100 patients and healthy donors to study T-cells, a key part of the immune system. They also plan to test a lab technique to restore T-cell funct…

This study looks at how the drug eloralintide enters the bloodstream and leaves the body in people with severe kidney disease or kidney failure, compared to healthy volunteers. About 28 participants will receive a single shot under the skin. The study lasts about 14 weeks and doe…

This study compares three ways to check for fluid overload (too much fluid in the body) in people doing dialysis at home. Researchers will ask about symptoms, do a physical exam, and use a safe ultrasound of the lungs. The goal is to find which method works best to help prevent h…